7-(benzyloxy)-4-(chloromethyl)-2H-chromen-2-one | 828265-69-6

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 香豆素及其衍生物
• 英文名称: 7-(benzyloxy)-4-(chloromethyl)-2H-chromen-2-one
• 英文别名: 4-Chloromethyl-7-benzyloxy-2H-chromen-2-one；4-(chloromethyl)-7-phenylmethoxychromen-2-one
• CAS: 828265-69-6
• 化学式: C₁₇H₁₃ClO₃
• 分子量: 300.741
• InChiKey: DPKFXKRLUDIOHP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  7-(benzyloxy)-4-(chloromethyl)-2H-chromen-2-one 在 sodium azide 作用下， 以 乙醇 为溶剂， 反应 2.0h， 以45%的产率得到4-(azidomethyl)-7-benzyloxy-2H-chromen-2-one
  参考文献：
  名称：

  Discovery of a Novel Class of Potent Coumarin Monoamine Oxidase B Inhibitors: Development and Biopharmacological Profiling of 7-[(3-Chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one Methanesulfonate (NW-1772) as a Highly Potent, Selective, Reversible, and Orally Active Monoamine Oxidase B Inhibitor

  摘要：

  In an effort to discover novel selective monoamine oxidase (MAO) B inhibitors with favorable physicochemical and pharmacokinetic profiles, 7-[m-halogeno)benzyloxy]coumarins bearing properly selected polar substituents at position 4 were designed, synthesized, and evaluated as MAO inhibitors. Several compounds with MAO-B inhibitory activity in the nanomolar range and excellent MAO-B selectivity (selectivity index SI > 400) were identified. Structure-affinity relationships and docking simulations provided valuable insights into the enzyme-inhibitor binding interactions at position 4, which has been poorly explored. Furthermore, computational and experimental studies led to the identification and biopharmacological characterization of 7-[(3-chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one methanesulfonate 22b (NW-1772) as an in vitro and in vivo potent and selective MAO-B inhibitor, with rapid blood-brain barrier penetration, short-acting and reversible inhibitory activity, slight inhibition of selected cytochrome P450s, and low in vitro toxicity. On the basis of this preliminary preclinical profile, inhibitor 22b might be viewed as a promising clinical candidate for the treatment of neurodegenerative diseases.

  DOI：

  10.1021/jm9010127
• 作为产物：
  描述：

  间苯二酚 在 硫酸 、 N,N-二异丙基乙胺 作用下， 以 乙醇 为溶剂， 生成 7-(benzyloxy)-4-(chloromethyl)-2H-chromen-2-one
  参考文献：
  名称：

  追逐 ChEs-MAO B 多靶点 4-氨甲基-7-苄氧基-2H-Chromen-2-酮

  摘要：

  研究了一系列 4-氨甲基-7-苄氧基-2H-色烯-2-酮，旨在鉴定多种胆碱酯酶（乙酰基和丁酰基、AChE 和 BChE）和单胺氧化酶 B (MAO B) 的潜在抑制剂抗阿尔茨海默病分子。从先前报道的有效 MAO B 抑制剂 (3) 开始，我们研究了苄氧基或碱性部分的单点修饰。体外筛选突出显示了三效化合物 (6、8、9、16、20)，显示出纳摩尔级选择性 MAO B 抑制作用以及低微摩尔水平下针对 ChE 的 IC50 值。对 AChE 进行酶动力学分析并对目标酶进行对接模拟，以深入了解作用机制和合理的结合模式。

  DOI：

  10.3390/molecules24244507

文献信息

• [EN] MAO-B SELECTIVE INHIBITOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF<br/>[FR] COMPOSÉS INHIBITEURS À SÉLECTIVITÉ MAO-B, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET UTILISATIONS CORRESPONDANTES
  申请人：UNIV BRITISH COLUMBIA

  公开号：WO2015027324A1

  公开（公告）日：2015-03-05

  Described herein are a series of compounds having the structure of Formula I for use in the inhibition of MAO and uses thereof for the treatment of a barrier disease, obesity, solid epithelial cell tumor metastasis, diabetes, an auto-immune and inflammatory disease or a cardiometabolic disorder.

  本文描述了一系列具有公式I结构的化合物，用于抑制MAO并用于治疗屏障疾病、肥胖、实体上皮细胞肿瘤转移、糖尿病、自身免疫和炎症性疾病或心脏代谢紊乱。
• Design, Synthesis, and 3D QSAR of Novel Potent and Selective Aromatase Inhibitors
  作者：Francesco Leonetti、Angelo Favia、Angela Rao、Rosaria Aliano、Anja Paluszcak、Rolf W. Hartmann、Angelo Carotti

  DOI：10.1021/jm049535j

  日期：2004.12.1

  imidazole or triazole ring linked to a fluorene (A), indenodiazine (B), or coumarin scaffold (C) are reported. Properly substituted coumarin derivatives displayed the highest aromatase inhibitory potency and selectivity over 17-alpha-hydroxylase/17-20 lyase. The modeling of the aromatase inhibition data by Comparative Molecular Field Analysis (CoMFA/GOLPE 3D QSAR approach) led to the development of a PLS

  报道了一系列新的芳香酶抑制剂的设计，合成和生物学评估，这些抑制剂带有与芴（A），茚并二嗪（B）或香豆素骨架（C）连接的咪唑或三唑环。与17-α-羟化酶/ 17-20裂解酶相比，正确取代的香豆素衍生物显示出最高的芳香酶抑制能力和选择性。通过比较分子场分析（CoMFA / GOLPE 3D QSAR方法）对芳香化酶抑制数据进行建模，导致了具有良好拟合和预测能力（n = 22，ONC = 3，r（2）= 0.949， s = 0.216，而q（2）= 0.715）。
• Substituted Aminoalkyl- and Amidoalkyl-Benzopyran Derivatives
  申请人：Carotti Angelo

  公开号：US20090005436A1

  公开（公告）日：2009-01-01

  This invention is related to novel aminoalkyl- and amidoalkyl-benzopyran derivatives of the following general formula (I) wherein: the group is a substituent in position 6 or 7 wherein: R is an aromatic mono- or bi-cyclic carbocyclic ring or a mono- or bi-cyclic heterocyclic ring radical, said rings being optionally substituted by one or two substituents selected from (C 1 -C 5 ) straight or branched alkyl, (C 1 -C 5 ) straight or branched alkoxy, hydroxy, halogen and trifluoromethyl; m is zero or an integer from 1 to 3; n, p, R 1 and R 2 are as herein indicated and R 3 and R 4 are both hydrogen or taken together represent an oxygen atom, and the pharmaceutically acceptable salts thereof. The compounds that are active as selective and reversible MAO-B inhibitors in vitro and in vivo, are useful as medicaments for the prevention and the treatment of CNS degenerative disorders.

  本发明涉及以下通式（I）的新型氨基烷基和酰胺烷基苯并吡喃衍生物： 其中：基团是6或7位的取代基，其中：R是芳香单环或双环碳环或单环或双环杂环基团，所述环可以选择地由一或两个取代基取代，所述取代基选择自（C1-C5）直链或支链烷基，（C1-C5）直链或支链烷氧基，羟基，卤素和三氟甲基；m为零或1至3的整数；n、p、R1和R2如本文所示，而R3和R4均为氢或一起代表氧原子，以及其药学上可接受的盐。 这些化合物在体外和体内作为选择性和可逆的MAO-B抑制剂具有活性，可用作预防和治疗中枢神经系统退行性疾病的药物。
• MAO-B Selective Inhibitor Compounds, Pharmaceutical Compositions Thereof and Uses Thereof
  申请人：THE UNIVERSITY OF BRTISH COLUMBIA

  公开号：US20160207878A1

  公开（公告）日：2016-07-21

  Described herein are a series of compounds having the structure of Formula I: for use in the inhibition of MAO and uses thereof for the treatment of a barrier disease, obesity, solid epithelial cell tumor metastasis, diabetes, an auto-immune and inflammatory disease or a cardiometabolic disorder.

  本文描述了一系列具有I式结构的化合物，用于抑制MAO并用于治疗障碍性疾病、肥胖症、实体上皮细胞肿瘤转移、糖尿病、自身免疫和炎症性疾病或心脏代谢紊乱的用途。
• MAO-B selective inhibitor compounds, pharmaceutical compositions thereof and uses thereof
  申请人：The University of British Columbia

  公开号：US10196345B2

  公开（公告）日：2019-02-05

  Described herein are a series of compounds having the structure of Formula I: for use in the inhibition of MAO and uses thereof for the treatment of a barrier disease, obesity, solid epithelial cell tumor metastasis, diabetes, an auto-immune and inflammatory disease or a cardiometabolic disorder.

  本文描述了一系列具有式 I 结构的化合物： 用于抑制 MAO 及其在治疗屏障疾病、肥胖症、实体上皮细胞肿瘤转移、糖尿病、自身免疫性和炎症性疾病或心脏代谢紊乱方面的用途。